LLY
Eli Lilly and Company
NYSE · Healthcare · Drug Manufacturers - General · US
$1,145.09
−1.25%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 79.7B | 65.2B | 45.0B | 34.1B | 28.5B |
| Cost of Revenue | 12.7B | 10.6B | 8.4B | 7.1B | 6.6B |
| Gross Profit | 66.9B | 54.6B | 36.6B | 27.0B | 21.9B |
| Operating Expenses | |||||
| R&D Expense | 14.6B | 13.3B | 11.0B | 9.3B | 7.2B |
| SG&A Expense | 12.4B | 11.1B | 8.1B | 6.9B | 6.1B |
| General & Admin Expense | 6.1B | 11.1B | 8.1B | 6.9B | 6.1B |
| Selling & Marketing Expense | 6.4B | — | — | — | — |
| Other Expenses | 4.9B | 487.5M | — | — | — |
| Total Operating Expenses | 31.9B | 24.9B | 19.1B | 16.3B | 13.3B |
| Cost and Expenses | 44.7B | 35.5B | 27.5B | 23.3B | 19.9B |
| Operating Income (EBIT) | 35.0B | 29.7B | 17.5B | 10.8B | 8.7B |
| Non-Operating | |||||
| Interest Income | 65.0M | 153.3M | 175.2M | 173.6M | 62.8M |
| Interest Expense | 979.6M | 795.3M | 780.6M | 485.9M | 331.6M |
| Net Interest Income | (914.6M) | (642.0M) | (605.4M) | (312.3M) | (268.8M) |
| Other Non-Op Income/Expense | (1.4B) | (4.0B) | (4.8B) | (4.2B) | (1.8B) |
| Non-Operating Income (excl Interest) | 912.6M | 3.3B | 4.0B | 3.7B | 1.5B |
| EBT (Pre-Tax Income) | 33.6B | 25.7B | 12.7B | 6.6B | 6.8B |
| Income Tax Expense | 6.9B | 5.1B | 2.1B | 1.3B | 561.6M |
| Bottom Line | |||||
| Net Income | 26.7B | 20.6B | 10.6B | 5.2B | 6.2B |
| Earnings from Cont. Ops | 26.7B | 20.6B | 10.6B | 5.2B | 6.2B |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 26.7B | 20.6B | 10.6B | 5.2B | 6.2B |
| Per Share | |||||
| Basic EPS | $29.85 | $23.00 | $11.76 | $5.83 | $6.57 |
| Diluted EPS | $29.80 | $22.95 | $11.71 | $5.80 | $6.57 |
| Revenue Per Share | $89.27 | $72.58 | $50.01 | $37.94 | $30.04 |
| Shares | |||||
| Basic Shares Outstanding | 892.4M | 898.0M | 900.6M | 899.4M | 950.2M |
| Diluted Shares Outstanding | 893.7M | 898.0M | 904.1M | 903.3M | 950.2M |
| Profitability Metrics | |||||
| EBITDA | 35.2B | 27.9B | 15.2B | 8.6B | 8.7B |
| D&A | 1.1B | 1.6B | 1.8B | 1.5B | 1.5B |
| EBIT | 34.1B | 26.4B | 13.5B | 7.0B | 7.1B |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026